Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?

PURPOSE: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities on discontinuation of endocrine therapy in clinical practice. METHODS: We identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemp, Anna, Preen, David B, Saunders, Christobel, Boyle, Frances, Bulsara, Max, Malacova, Eva, Roughead, Elizabeth E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058005/
https://www.ncbi.nlm.nih.gov/pubmed/24936397
http://dx.doi.org/10.1186/2193-1801-3-282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058005/
https://www.ncbi.nlm.nih.gov/pubmed/24936397
http://dx.doi.org/10.1186/2193-1801-3-282

Ejemplares similares